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Abstract
Introduction: Hyperglycemia and insulin resistance are well-known features of critical illness and impact the
mortality rate, especially in sepsis. Retinol binding protein 4 (RBP4) promotes insulin resistance in mice and is
systemically elevated in patients with obesity and type 2 diabetes. We investigated the potential role of RBP4 in
critically ill patients.
Methods: We conducted a prospective single-center study of serum RBP4 concentrations in critically ill patients.
One hundred twenty-three patients (85 with sepsis, 38 without sepsis) were studied at admission to a medical
intensive care unit (ICU) before initiation of specific intensive care treatment measures and compared to 42 healthy
nondiabetic controls. Clinical data, various laboratory parameters and metabolic and endocrine functions were
assessed. Patients were followed for approximately 3 years.
Results: Serum RBP4 was significantly reduced in ICU patients, independently of sepsis, as compared to healthy
controls (P < 0.001). Patients with liver cirrhosis as the primary underlying diagnosis for ICU admission had
significantly lower RBP4 levels as compared with other ICU patients. Accordingly, in all ICU patients, serum RBP4
closely correlated with liver function and increased with renal failure. No significant differences of serum RBP4
concentrations in septic patients with pulmonary or other origins of sepsis or nonseptic patients could be revealed.
Acute phase proteins were inversely correlated with RBP4 in sepsis patients. RBP4 did not differ between patients
with or without obesity or preexisting diabetes. However, serum RBP4 levels correlated with endogenous insulin
secretion (C-peptide) and insulin resistance (HOMA index). Low serum RBP4 upon admission was an adverse
predictor of short-term survival in the ICU, but was not associated with overall survival during long-term follow-up.
Conclusions: Serum RBP4 concentrations are significantly reduced in critically ill patients. The strong associations
with hepatic and renal function, insulin resistance and acute mortality collectively suggest a role of RBP4 in the
pathogenesis of critical illness, possibly as a negative acute phase reactant, and allow a proposition as a potential
novel biomarker for ICU patients.
Introduction
Hyperglycemia, glucose intolerance and insulin resis-
tance are common features of critically ill patients, espe-
cially in patients with sepsis or septic shock and even in
those without a history of diabetes [1-3]. Maintenance
of normoglycemia (blood glucose levels of 110 mg/dL)
with intensive insulin therapy has been shown to
improve survival and reduce morbidity in patients with
prolonged critically illness after cardiac surgery [4],
whereas its beneficial effect on the outcome of patients
in medical intensive care units (ICU) is controversial
[5,6]. In patients with obesity, metabolic syndrome and
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type 2 diabetes, several adipocytokines have been identi-
fied that mediate agonistic and antagonistic effects on
insulin resistance [7,8]. In these patients, chronic inflam-
matory conditions apparently promote adipocytic secre-
tion of mediators of insulin resistance into the
circulation, thereby providing a link between adipocyto-
kines, inflammation and systemic insulin resistance [7,8].
Retinol binding protein 4 (RBP4), a 21-kDa protein
synthesized in the liver and adipose tissue, has recently
been described as an adipokine involved in the develop-
ment of insulin resistance in mice and humans [9,10].
In the past, RBP4 was solely recognized for its role as
the specific transport protein for vitamin A (retinol) in
the circulation, whose function is to deliver hydrophobic
retinol from the liver to target tissues [11]. In animal
models of insulin resistance, the expression of RBP4
was strongly induced in adipose tissue, and systemic
release of RBP4 appeared to be a crucial signal for the
development of systemic insulin resistance [10,12].
These results have been translated into the pathogenesis
of insulin resistance in humans. Serum RBP4 correlated
positively with the presence of insulin resistance in indi-
viduals with obesity, impaired glucose tolerance or type
2 diabetes [13,14]. Elevated serum RBP4 concentrations
were an independent predictive biomarker at early
stages of insulin resistance identifying individuals at risk
of developing diabetes and were even found in healthy
individuals with a strong family history of type 2 dia-
betes [13,14].
Recently, low levels of serum RBP4 have been
reported in critical ill patients with sepsis of pulmonary
origin compared to nonseptic patients [15]. However, it
remained unclear whether this observation was related
to sepsis or whether it could be extrapolated to all criti-
cally ill patients, because this study analyzed only
patients with a respiratory disease as the main reason
for admission to the ICU. Moreover, the pathogenic
and/or diagnostic relevance of RBP4 in ICU patients is
presently not known [15]. Various essential therapeutic
interventions in the initial phase of intensive care treat-
ment, e.g., fluid challenge, insulin therapy, nutritional
support and renal replacement therapies, potentially
influence concentrations of biomarkers. At present,
there is a lack of studies investigating the regulation of
adipocytokines in critical illness at the point of admis-
sion before any substantial therapeutic interference.
Our study investigated serum RBP4 concentrations in
a large cohort of “untouched,” treatment-naive critically
ill patients (septic and nonseptic patients) from a medi-
cal ICU at the moment of admission to the ICU. We
aimed at understanding the potential involvement of
RBP4 in the pathogenesis of insulin resistance in critical
illness, its regulation in severe systemic inflammation
and its potential clinical use as a biomarker in ICU
patients. We demonstrate that serum RBP4 levels were
significantly reduced in ICU patients as compared to
controls, independent of etiology of critical illness or
origin of sepsis (pulmonary versus nonpulmonary), and
they were closely related to liver and kidney function.
The dysregulation of serum RBP4 in ICU patients was
not associated with preexisting diabetes or obesity, but
might contribute to the insulin-resistant state of the cri-
tically ill patients. High RBP4 levels were indicative of a
beneficial short-term course of disease, but did not pre-
dict the overall survival of the patients in a 3-year fol-
low-up period.
Materials and methods
Patients and controls
From the medical ICU at the University Hospital
Aachen, Germany, a tertiary care university hospital,
patients were prospectively enrolled at the time of ICU
admission. Patients who were expected to stay <72
hours at the ICU (e.g., postinterventional observation,
acute intoxication) were not asked to participate in this
study [16]. Written informed consent was obtained from
each participant or his or her spouse, and the study was
approved by the local ethics committee (ethics commit-
tee of the University Hospital Aachen, RWTH-Univer-
sity, Aachen, Germany, reference number EK 150/06).
Patient data, blood samples and clinical information
were collected prospectively. Owing to lack of sufficient
material, 123 of initially 170 consecutively recruited
patients were included in the current study. Median
duration of stay at the ICU was 8 days (range, 1-137
days), and median duration of stay at the hospital was
26.5 days (range, 2-151 days). The clinical course of the
patients after discharge was followed by contacting the
patients and/or their primary care physician up to 3
years after entry into this study (median observation
time, 591 days; range, 29-884 days). Patients were cate-
gorized as having severe sepsis (acute organ dysfunction
secondary to infection) and septic shock (severe sepsis
plus hypotension not reversed with fluid resuscitation),
hereafter called sepsis, according to the definitions in
current guidelines [17], or as being nonsepsis. Sepsis
patients were subdivided into cohorts of sepsis of pul-
monary and nonpulmonary origin on the basis of the
clinical and radiological classification performed upon
admission.
Forty-two healthy, nondiabetic blood donors (30 male,
12 female; median age, 53 years; range, 24-68 years)
who had normal blood counts, normal liver enzymes
and normal C-reactive protein levels served as controls.
Comparative and laboratory variables
The ICU patients were compared by age, sex and sever-
ity of illness using the score on the Acute Physiology
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and Chronic Health Evaluation (APACHE) II obtained
at admission and the simplified acute physiology score
(SAPS) 2 [16]. Laboratory parameters were routinely
assessed at admission, recorded and analyzed.
Quantification of RBP4 serum levels and other
adipocytokines
Peripheral venous blood samples were obtained at
admission before therapeutic intervention, immediately
placed on ice, centrifuged and stored at -80°C. All mea-
surements were performed in a blinded fashion by the
same investigator. RBP4 serum concentrations were
measured using an enzyme-linked immunosorbent assay
according to the manufacturer’s instructions (Immun-
diagnostik AG, Bensheim, Germany) [18]. Serum resis-
tin, ghrelin, adiponectin and C-peptide were measured
as described previously [19-21]. Insulin sensitivity was
assessed by the homeostasis model assessment (HOMA)
index using the HOMA Calculator V. 2.2.2 from the
University of Oxford, UK [20,22].
Statistical analysis
Analyses were performed with SPSS 12.0 software
(SPSS, Munich, Germany). Owing to skewed distribu-
tions of most variables, the median and range are given.
Differences between two groups were assessed by the
Mann-Whitney U test or between more than two
groups by Kruskal-Wallis analysis of variance and the
Mann-Whitney U test for post hoc analysis [18]. Com-
parisons between subgroups are illustrated with boxplot
graphics, where the black bold line indicates the median
per group, the box represents 50% of the values and
horizontal lines show minimum and maximum values
of the calculated nonoutlier values; asterisks and open
circles indicate outlier values. The correlations between
variables were analyzed using the Spearman correlation
tests. Values of P < 0.05 were considered statistically
significant. The prognostic value of the variables was
tested by univariate and multivariate analyses in the
Cox regression model. After significant results from the
uni- and multivariate Cox regression analyses, Kaplan-
Meier curves and log-rank test calculations were per-
formed subsequently for different cutoff values for
RBP4 (9, 10, 11, 12, 13, 14 and 15 mg/L). The threshold
of 12 mg/L RBP4 yielded the highest log-rank values.
Kaplan-Meier curves were plotted to display the impact
on survival [23].
Results
RBP4 serum levels are significantly reduced in ICU
patients compared with healthy controls, independent of
the presence of sepsis
The median serum concentration of RBP4 in healthy
controls was 28.1 mg/L (range, 18.8-255.6 mg/L, 90%
interval, 20.0-53.8 mg/L) as anticipated from previous
studies using the same assay [13,18]. In our cohort of
nondiabetic healthy controls, serum RBP4 did not corre-
late with the body mass index (BMI), and there was no
difference between male and female volunteers. Criti-
cally ill ICU patients had significantly reduced serum
RBP4 concentrations compared with healthy controls
(median, 16.1 vs. 28.1 mg/L, P < 0.001; Figure 1a,
Table 1). Again, male and female patients did not differ
in serum RBP4.
As inflammatory disorders could considerably impact
serum RBP4 concentrations, we next compared patients
with sepsis (n = 85) with patients without sepsis
(n = 38). In the sepsis group, the focus of infection was
either pulmonary (n = 45), abdominal (n = 19) or other
(n = 21, e.g., catheter-associated, urogenital or
unknown). In the nonsepsis group, the etiology of criti-
cal illness was decompensated liver cirrhosis (n = 11),
cardiopulmonary (n = 16) or other diseases (n = 11).
Interestingly, serum RBP4 did not differ significantly
between patients with sepsis (median 15.2 mg/L) and
without sepsis (median 20.0 mg/L; Figure 1b). With
respect to several other clinical parameters (APACHE II
score, mechanical ventilation, vasopressor demand),
patients with or without sepsis did not differ, but
patients with sepsis had a higher ICU and overall mor-
tality as well as significantly longer ventilation duration
(Table 2).
RBP4 serum levels are associated with liver and renal
function and are inversely correlated with inflammatory
biomarkers
A recent study reported reduced RBP4 serum levels in
patients with sepsis of pulmonary origin [15]. To investi-
gate the regulation of RBP4 in patients with different
etiologies of sepsis and septic shock, we performed
extensive subgroup analyses. However, there was no dif-
ference in RBP4 serum concentrations between patients
with sepsis of pulmonary or nonpulmonary origin (Fig-
ure 2a). Furthermore, patients with pulmonary and non-
pulmonary sepsis did not differ in baseline clinical
parameters or in inflammatory markers such as CRP
(Figure 2b, and data not shown).
Interestingly, ICU patients with liver cirrhosis
displayed the lowest RBP4 serum levels among all sub-
groups (Figure 2a). Liver function could be identified as
a strong predictor of serum RBP4, as RBP4 levels
directly correlated with parameters indicating the liver’s
biosynthetic capacity, namely, albumin (r = 0.404, P <
0.001; Figure 3a), total protein (r = 0.272, P = 0.003),
pseudocholinesterase activity (r = 0.491, P < 0.001;
Figure 3b), IGF-1 concentrations (r = 0.403, P < 0.001),
prothrombin time (r = 0.524, P < 0.001) and inversely
with bilirubin (e.g., conjugated bilirubin; r = -0.434, P <
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0.001). Of note, RBP4 serum concentrations remained
significantly (P < 0.001, Mann-Whitney U test) elevated
in controls (n = 42, median 28.1; range, 18.8-
255.6 mg/L) compared to ICU patients without cirrhosis
(n = 112, median 16.5, range 0.3-147.6 mg/L).
Serum RBP4 concentrations were also correlated with
markers of renal failure, specifically increasing creatinine
(r = 0.493, P < 0.001; Figure 3c), urea (r = 0.389, P <
0.001), cystatin C (r = 0.381, P < 0.001) and decreasing
glomerular filtration rate (GFR; r = -0.526, P < 0.001).
Although there was no significant difference between
septic and nonseptic patients, systemic inflammatory mar-
kers were associated with serum RBP4 concentrations.
Classical biomarkers of systemic inflammatory responses
were inversely associated with serum RBP4, such as C-
reactive protein (r = -0.204, P = 0.025) or interleukin-6
levels (r = -0.272, P = 0.019). RBP4 thereby displayed char-
acteristics of a negative acute phase reactant [24]. How-
ever, this association was observed only in sepsis patients.
Preexisting diabetes or obesity do not significantly
impact RBP4 serum levels in ICU patients, but serum
RBP4 correlates with insulin secretion and resistance
Initial studies linked elevated serum RBP4 to overt or
impending insulin resistance in lean, obese and type 2
diabetic subjects [13]. To understand potential patho-
physiological consequences of reduced RBP4 levels in
ICU patients, we analyzed associations between serum
RBP4 and insulin resistance as well as diabetes. Patients
with a preexisting type 2 diabetes (n = 42) did not differ
from patients without diabetes (n = 81; Figure 4a) in
serum RBP4 concentrations. Consequently, serum RBP4
was not correlated to the glycosylated hemoglobin
(HbA1c) levels in ICU patients either. Furthermore,
serum RBP4 did not correlate with the patients’ BMI
(data not shown), and obese patients (defined as BMI >
30, n = 30) did not show higher serum RBP4 than
patients without severe obesity (BMI ≤ 30, n = 75; Fig-
ure 4b).
Although serum RBP4 did not correlate with serum
glucose on admission to the ICU, serum RBP4 corre-
lated with the C-peptide (r = 0.305, P = 0.001; Figure
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Figure 1 Serum retinol binding protein 4 (RBP4) concentrations in critically ill patients. (a) Serum RBP4 levels are significantly (P < 0.001,
Mann-Whitney U test) reduced in critically ill patients (n = 123) as compared to healthy controls (n = 42). (b) No significant differences were
detected between ICU patients with sepsis and nonseptic etiology of critical illness. Boxplots are displayed, where the bold line indicates the
median per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of the calculated nonoutlier
values; asterisks and open circles indicate outlier values.
Table 1 Comparison between ICU patients and healthy
controls
Parameter Controls ICU patients P value
Number 42 123
Sex (male/female) 30/12 81/42 n.s.
Age median (range)
(yr)
53
(24-68)
64
(18-81)
<0.001
BMI median (range)
(m2/kg)
27.0
(22.0-57.0)
26.1
(15.3-59.5)
n.s.
RBP4 median (range) (mg/L) 28.1
(18.8-255.6)
16.1
(0.3-147.6)
<0.001
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4c), with the insulin resistance as calculated by the
HOMA index (HOMA-IR; r = 0.248, P = 0.009;
HOMA-S, r = -0.248, P = 0.009; Figure 4d). This asso-
ciation of serum RBP4 to endogenous insulin secretion
and insulin resistance was in sharp contrast to other
adipocytokines. RBP4 serum levels did not correlate
with adiponectin, resistin or ghrelin serum concentra-
tions, nor did adiponectin, resistin or ghrelin correlate
with insulin resistance (data not shown).
High RBP4 levels are a positive predictor of short-term
survival at the ICU, but do not influence overall survival
of ICU patients
We next analyzed whether serum RBP4 concentrations
upon ICU admission may predict clinical outcome and
mortality. Interestingly, patients who died during ICU
hospitalization (33/123) displayed significantly lower
serum RBP4 concentrations than the patients who were
surviving (Figure 5a). The beneficial prognostic impact
of high RBP4 levels on ICU survival was confirmed by
Cox regression analysis (P = 0.031). By multivariate Cox
regression analysis, the effect of RBP4 on ICU survival
was independent of age, BMI, renal function (creatinine,
GFR) and CRP, but indistinguishable from liver func-
tion. Two models were tested in multivariate Cox
regression analyses, using ICU outcome (survival/death)
as the endpoint. The first model included RBP4, age,
BMI, creatinine, GFR (cystatin C-based) and CRP, and
RBP4 was the only parameter that remained indepen-
dently significant (P = 0.041) to predict ICU outcome in
this combination. The second model combined RBP4
and markers of hepatic dysfunction (albumin, interna-
tional normalized ratio, pseudocholinesterase). In this
model, pseudocholinesterase remained the only indepen-
dently significant (P < 0.001) parameter predicting ICU
survival. If all parameters were combined, pseudocholi-
nesterase was the dominant predictor for ICU outcome.
Using Kaplan-Meier survival curves with a cutoff for
serum RBP4 concentrations of 12 mg/L (Figure 5b),
high RBP4 levels were a significant positive prognostic
marker for ICU survival (log-rank test, 10.96; P =
0.0009). On the other hand, serum RBP4 levels did not
predict the overall survival of the ICU patients in the
approximately 3-year follow-up (Figure 5c), indicating
that the prognostic relevance and potentially also the
pathogenic involvement of RBP4 is restricted to the
acute illness.
Discussion
RBP4, the circulating transporter for vitamin A, has
recently been recognized as an important mediator of
insulin resistance in mice and humans, but its potential
role in sepsis or critical illness is presently a matter
being researched. A recent single-center study reported
low circulating levels of RBP4 in patients with acute cri-
tical illness of respiratory etiology compared to healthy
controls. In the cohort of septic patients with identified
pulmonary focus, lower levels of RBP4 were found than
in nonseptic patients [15]. The authors hypothesized
that an acute decrease of RBP4 concentrations could be
explained by reduced synthesis or increased removal by
extravasation due to capillary leakage or increased meta-
bolic clearance [15].
Our study shows that reduced serum concentrations
of RBP4 are a general response in critically ill patients,
independent of the origin of the critical illness (sepsis or
nonsepsis). The source of circulating RBP4 in critically
ill patients appears to be primarily a combination of two
factors: hepatic synthesis and renal clearance.
It is well established that the liver is the main source
of RBP4 in humans [11,12], although adipocyte RBP4
Table 2 Baseline patient characteristics and RBP4 serum
concentrations
Parameter All
patients
Sepsis Nonsepsis
Number 123 85 38
Sex (male/female) 81/42 56/29 25/13
Age median (range)
(yr)
64
(18-81)
64
(21-81)
60
(18-79)
APACHE-II score median (range) 14
(0-31)
14
(0-31)
14
(0-31)
SAPS2 score median (range) 42
(0-80)
42
(0-79)
42
(13-80)
ICU days median (range) 8
(1-137)
10
(1-137)
5.5**
(1-45)
Hospital days median (range) 26
(2-151)
30
(3-151)
14**
(2-65)
Death during ICU n (%) 33 (27%) 25 (29%) 8 (21%)
Death during follow-up n (%) 59 (48%) 41 (48%) 18 (47%)
30-day mortality (%) 26.0 25.9 26.3
60-day mortality (%) 34.4 35.7 31.6
90-day mortality (%) 40.2 42.7 34.3
180-day mortality (%) 43.5 46.9 35.3
1-year mortality (%) 52.4 54.1 48.4
Mechanical ventilation
n (%)
78 (63%) 53 (62%) 25 (66%)
Ventilation time median (range)
(h)
38
(0-2966)
80
(0-2966)
24**
(0-755)
pre-existing diabetes
n (%)
42 (34%) 27 (32%) 15 (40%)
BMI median (range)
(m2/kg)
26.1
(15.3-59.5)
26.2
(15.3-
59.5)
25.4
(19.0-53.3)
RBP4 median (range) (mg/L) 16.1
(0.3-147.6)
15.2
(0.3-
147.6)
20.0
(1.0-118.6)
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, simplified
acute physiology score; ICU, intensive care unit; BMI, body mass index
Significant differences between sepsis and nonsepsis patients are marked by
*P < 0.05 or **P < 0.001.
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secretion has been linked to obesity, insulin resistance
and type 2 diabetes [12,13,25]. Consequently, patients
with chronic liver diseases and liver cirrhosis have sig-
nificantly decreased RBP4 serum concentrations, and
serum RBP4 is directly linked to liver function in these
patients [18,26,27]. Interestingly, we also observed a
close correlation between the hepatic biosynthetic func-
tion and serum RBP4 in ICU patients, suggesting that
circulating serum RBP4 is a direct consequence of hepa-
tic synthesis comparable to the immediately increased
hepatic synthesis of many acute phase proteins in criti-
cal illness. Furthermore, the lack of correlation between
RBP4 and other adipokines indicates that the adipose
tissue does not extensively contribute to serum RBP4 in
patients with critical illness.
In addition, it is well established that serum RBP4 is
increased in patients with chronic renal failure, making
renal clearance a relevant confounding factor for serum
RBP4 concentrations in patients with diabetes or renal
disease [28,29]. As acute renal failure, mainly of prerenal
origin during hemodynamic deterioration, is a classical
feature of critically ill patients, our study demonstrated
a direct correlation between increasing serum RBP4 and
decreasing renal function in ICU patients. In multivari-
ate analysis, hepatic and renal biomarkers independently
correlated with serum RBP4 (data not shown), indicating
that both mechanisms occur in parallel in critically ill
patients regulating serum RBP4 levels. However, overall
RBP4 serum levels remained significantly lower than in
healthy controls.
Our results further indicate that the elevated serum
RBP4 might be involved in the development of insulin
resistance in ICU patients. Hyperglycemia and insulin
resistance are well-known features of critical illness and
affect the mortality rate, especially in septic patients
[1,30,31]. Prior studies have confirmed excessive endogen-
ous insulin secretion during sepsis, which represented an
important pathogenetic and prognostic factor in ICU
patients [30,32]. We show here that the circulating RBP4
level in ICU patients is not the result of preexisting dia-
betes or glucose intolerance (as reflected by HbA1c or
plasma glucose). However, we did see a correlation with
current endogenous insulin secretion, reflected by elevated
C-peptide levels, and insulin resistance as calculated by
the HOMA index, indicating that circulating RBP4 levels
in ICU patients may contribute to the insulin-resistant
state frequently observed in critically ill patients. Further
studies in appropriate animal models of experimental sep-
sis are needed to clarify the potential pathogenetic role
and metabolic consequences of RBP4 in critical illness.
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Figure 2 Impact of primary diagnosis on serum RBP4 concentrations at admission to the medical intensive care unit (ICU). (a) Among
critically ill patients, serum RBP4 levels do not differ between patients with sepsis of pulmonary origin as compared to sepsis of nonpulmonary
(non-pulmo.) origin. Lowest RBP4 levels are found in patients with decompensated liver cirrhosis. P values (Mann-Whitney U test) are given in
the figure. (b) No significant differences are detected for C-reactive protein (CRP) concentrations in ICU patients with either sepsis of pulmonary
or nonpulmonary origin, but both sepsis groups show higher values than the nonsepsis groups. Boxplots are displayed, where the bold line
indicates the median per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of the
calculated nonoutlier values; asterisks and open circles indicate outlier values.
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The reduction of serum RBP4 in critically ill patients
compared to controls was also of direct prognostic rele-
vance. Our data revealed an association between low
RBP4 and higher short-term mortality on ICU, whereas
long-term survival was not affected. The underlying
pathomechanisms are currently unclear. One explana-
tion could be that this is a simple epiphenomenon as
high(er) RBP4 levels may indicate preserved liver func-
tion; along this line, high “classical” biomarkers of liver
function are also associated with a beneficial outcome
(data not shown), and the predictive value of serum
RBP4 for ICU survival was statistically indistinguishable
from liver function in multivariate Cox regression
analysis.
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Figure 3 Impact of organ dysfunction on serum RBP4 in critically ill patients. (a and b) Parameters indicating the hepatic biosynthetic
capacity, such as serum albumin concentrations or the pseudocholinesterase acitvity, are positively correlated with serum RBP4 concentrations.
(c) Serum RBP4 is elevated in ICU patients with renal failure, as demonstrated exemplarily by the correlation with serum creatinine. Spearman
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On the other hand, other explanations should be consid-
ered. Interestingly, serum RBP4 levels were negatively cor-
related with markers of inflammation. This raises the
possibility that RBP4 could be an important component of
the so-called anti-acute phase proteins [24], at least in
patients with sepsis. In line with this possibility, decreasing
serum RBP4 levels have been reported after acute surgery
[33]. Functionally, elevated circulating RBP4 increased
blood glucose in mouse models by inhibiting insulin sig-
naling in skeletal muscle and upregulating gluconeogenesis
through increased expression of the gluconeogenic
enzyme phosphoenolpyruvate carboxykinase (PEPCK) in
n=81 n=42
0
20
40
60
80
100
se
ru
m
R
B
P4
 (m
g/
L)
no diabetes diabetes
n=75 n=30
0
20
40
60
80
100
BMI ≤ 30 BMI > 30
se
ru
m
R
B
P4
 (m
g/
L)
0 2 4 6 8 10 12 14
0
20
40
60
80
100
C-Peptide (nmol/L)
se
ru
m
R
B
P4
 (m
g/
L)
0 50 100 150 200
0
20
40
60
80
100
se
ru
m
R
B
P4
 (m
g/
L)
HOMA-insulin sensitivity
r= 0.305
p =0.001
r= -0.248
p =0.009
n.s. n.s.
A B
C D
Figure 4 Association of serum RBP4 with diabetes, obesity and insulin resistance in critically ill patients. (a and b) Serum RBP4 levels do
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values are given.
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the liver [12]. The concomitant reduction in muscular glu-
cose uptake and increase in hepatic glucose output could
possibly favor an adequate stress response in the initial
phase of critical illness and sepsis, which would explain
the positive association between relatively high RBP4 and
recovery from acute illness.
Conclusions
Our study has demonstrated reduced serum RBP4 con-
centrations in critically ill patients prior to intensive
care treatment measures. RBP4 serum levels at ICU
admission appeared independent of underlying disease
etiology, but were strongly associated with hepatic and
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Figure 5 Prognostic relevance of serum RBP4 in critically ill patients. (a) Patients who die during the course of ICU treatment have
significantly (P = 0.004) lower serum RBP4 levels on admittance to ICU than survivors. Boxplots are displayed, where the black bold line indicates
the median per group, the box represents 50% of the values, and horizontal lines show minimum and maximum values of the calculated
nonoutlier values; asterisks and open circles indicate outlier values. (b) Kaplan-Meier survival curves of ICU patients (n = 123) are displayed, showing
that patients with high RBP4 levels (> 12 mg/L, black) have a decreased short-term mortality at ICU as compared to patients with low RBP4 (<12
mg/L, gray). P value from Cox regression analysis is given. (c) Kaplan-Meier survival curves of ICU patients show no difference with respect to the
long-term survival between patients with RBP4 levels (> 12 mg/L, black) and patients with low RBP4 (< 12 mg/L, gray). n.s., not significant.
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renal function. The correlation with insulin resistance
and the relation with the acute mortality collectively
suggest that RBP4 may have implications for the patho-
genesis of critical illness and could serve a novel bio-
marker for ICU patients. Future studies should consider
including RBP4 as a factor for multivariate analyses and
aim to unravel the kinetics of RBP4 levels in the time
course of critical illness.
Key messages
• Retinol-binding protein 4 (RBP4) has been sug-
gested to contribute to insulin resistance, a common
characteristic of critically ill patients with implica-
tions for adverse outcome.
• RBP4 serum levels are significantly reduced in cri-
tically ill patients as compared to healthy controls.
• RBP4 serum levels at ICU admission prior to
intensive care measures appeared independent of
underlying disease etiology.
• Serum RBP4 concentrations are closely related to
liver and kidney function and correlate with endo-
genous insulin secretion and resistance.
• The negative association of serum RBP4 with
inflammatory markers suggests a potential role in
the anti-acute phase response in critical illness.
• Low RBP4 levels are an adverse predictor of short-
term mortality at the ICU.
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